On 4 June 2020, orphan designation EU/3/20/2278 was granted by the European Commission to Clinical Network Services (NL) B.V., Netherlands, for rilzabrutinib (also known as PRN1008) for the treatment of immune thrombocytopenia.
In August 2020, Clinical Network Services (NL) B.V.changed name to Scendea (NL) B.V.
|Disease / condition||
Treatment of immune thrombocytopenia
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.